Ibrutinib in Combination with Rituximab or Lenalidomide/Rituximab for Untreated FL


Ibrutinib in Combination with Rituximab or Lenalidomide/Rituximab for Untreated FL
Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Jeff Sharman, MD (2/9/16)

Fowler N et al. Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: Results from a multicenter, Phase 2 study. Proc ASH 2015;Abstract 470.

Ujjani CS et al. Phase I study of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma (Alliance 051103). Proc ASH 2015;Abstract 471.

Dr Sharman is Director of Research at the Willamette Valley Cancer Institute and Medical Director of Hematology Research at The US Oncology Network in Eugene, Oregon.